The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic monitoring of DNA damage biomarkers in circulating tumor cells (CTCs) to assess the mechanism of action of the topoisomerase-1 (Topo1) inhibitor, NKTR-102.
Sujita Sukumaran
Employment or Leadership Position - ApoCell
Christopher Neal
Employment or Leadership Position - ApoCell
Jacky Woo
Employment or Leadership Position - ApoCell
Vladislava O. Melnikova
Employment or Leadership Position - ApoCell
Kenna Lynn Anderes
Employment or Leadership Position - ApoCell
Christine Taylor Brew
No relevant relationships to disclose
Darren W. Davis
Employment or Leadership Position - ApoCell
Ute Hoch
Employment or Leadership Position - Nektar
Stock Ownership - Nektar